Increasingnumber of synthetic PPARγ ligands is commercially availabletoday (e.g., troglitazone, rosiglitazone, pioglitazone, ciglitazone,muraglitazar) for treatment of type 2 diabetes complications. This evidence concerns the gene PPARG and type 2 diabetes mellitus.